血清糖类抗原125和人附睾蛋白4联合检测在卵巢癌诊断和分期中的意义

Clinical significance of combined detection of CA125 and HE4 in diagnosis and staging of ovarian cancer

目的探讨血清糖类抗原125(CA125)和人附睾分泌蛋白4(HE4)检测在卵巢癌早期诊断中的价值。方法电化学发光法检测149例卵巢癌患者(卵巢癌组)、120例良性卵巢肿瘤患者(肿瘤对照组)和100例健康体检者(正常对照组)血清CA125和HE4水平,并对3组研究对象的检测结果进行比较分析。结果卵巢癌组血清CA125、HE4水平明显高于其他2组(P<0.05);血清CA125和HE4联合检测阳性率明显高于单项检测(P<0.05);联合检测不同分期卵巢癌的阳性率显著高于单项检测(P<0.05)。以肿瘤对照组作为参照,联合检测的敏感度和阴性预测值明显高于单项检测(P<0.05);联合检测的诊断效率高于单项检测,且联合检测的诊断效率高于CA125的诊断效率(P<0.01)。结论CA125和HE4联合检测可以提高卵巢癌早期诊断的效率。

Objective To evaluate the value of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4 ) in the diagnosis of ovarian cancer. Methods The serum levels of CA125 and HE4 in 149 ovarian cancer patients (ovarian cancer group), 120 benign ovarian tumor patients ( tumor control group) and 110 health control women (health control group) were detected by electrochemiluminescence assay, the results of three groups were compared and analyzed. Results The serum CA125 and HE>4 levels in the ovarian cancer group were significantly higher than other 2 groups, and there was statistical significance on the difference ( P<0.05 ). The sensitivity and negative predictive value of the combined detection of serum CA125 and HE4 were higher than that of the single test, and there was statistical significance on the difference ( P<0.05 ). The diagnostic efficiency of combined detection was higher than that of single detection. Conclusion The combined detection of serum CA125 and HE4 could enhance the early diagnosis of ovarian cancer.